Vaccinogen Inc., a company that develops cancer vaccines, has moved its corporate headquarters from Frederick to Baltimore to take advantage of the city’s research institutions and biotechnology activity.
The company completed the relocation — to a 10,000-square-foot facility at 949 Fell Street — on Sunday.
“This places us in an ideal location to attract additional top scientific talent and business leaders to the company as we move forward with our phase III clinical trial of OncoVAX, a patient-specific immunotherapy for stage II colon cancer,” said President and CEO Andrew Tussing.
“This move signifies another important milestone for the company as we continue our mission to build a solid business that aims to help reduce the recurrence of cancer with personalized vaccines.”
Vaccinogen officials also cited the proximity to Baltimore/Washington International Thurgood Marshall Airport as another factor contributing to the move, which is the latest big announcement for the company this year.
At the end of January, Vaccinogen closed the second $10 million tranche of an $80 million financing campaign that it announced last year.
And, last month, the company added two people to its board of directors: Ronald Kaiser, an experienced entrepreneurship and finance expert, and Hakan Edstrom, who brings biotech development experience.
Additionally, the company brought Peter Morsing, a pharmaceutical executive, on board as the global head of business development and strategy.
OncoVAX is the company’s signature product currently under development. The treatment, which would use a patient’s own live cells to launch an immune response to fight the recurrence of colon cancer, is now in clinical trials.